Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 12/20 | 0.46 |
| ▸ | BACE1 | P56817 | 12/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | DRD3 | P35462 | 3/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892336 | 1.00 | CTSD (0.46) | CTSDBACE1DRD2DRD3HTR1D | |
| SCHEMBL10209459 | 0.87 | BACE1 (0.49) | CTSDBACE1DRD2DRD3HTR1D | |
| SCHEMBL892159 | 0.83 | CTSD (0.49) | CTSDBACE1 | |
| SCHEMBL12490380 | 0.77 | CTSD (0.47) | CTSDBACE1 | |
| SCHEMBL12491009 | 0.73 | BACE1 (0.47) | BACE1DRD2DRD3CHRM1DRD4 | |
| SCHEMBL12491005 | 0.73 | BACE1 (0.47) | BACE1DRD2DRD3CHRM1DRD4 | |
| SCHEMBL12491004 | 0.73 | BACE1 (0.47) | BACE1DRD2DRD3CHRM1DRD4 | |
| SCHEMBL891952 | 0.71 | BACE1 (0.64) | CTSDBACE1 | |
| SCHEMBL882561 | 0.71 | BACE1 (0.64) | CTSDBACE1 | |
| SCHEMBL876643 | 0.71 | BACE1 (0.34) | CTSDBACE1DRD2DRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | CTSD 224/4885BACE1 1/4885DRD2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.